Based in Scottsdale, Arizona, CND Life Sciences is a neurodegenerative disease diagnostics company dedicated to giving patients clarity sooner through minimally invasive, skin-based testing.
This spotlight is published in recognition of the World Parkinson Congress (WPC) taking place in Phoenix this May, a fitting moment to highlight the work of a company deeply committed to advancing care for patients with Parkinson’s and related neurodegenerative diseases
What Inspired CND’s Mission?
CND Life Sciences was born out of a simple but powerful question: What if cutaneous nerves within in the skin could confirm neurodegenerative disease? For decades, the pathological hallmarks of diseases like Parkinson’s were known, but patients were often left in diagnostic limbo for years. Their mission was to show that disease-defining proteins could be detected in the skin, a minimally invasive window into the nervous system. When it became clear that this approach could meaningfully change how clinicians diagnose and care for patients, they felt a responsibility to bring it out of academia and into everyday clinical practice. That commitment to turning rigorous science into practical tools that give patients clarity sooner continues to drive everything they do.
What Is CND Life Sciences Most Excited About in 2026?
What excites CND Life Sciences most about 2026 is the continued advancement of its science toward earlier detection, improved risk stratification, and more meaningful clinical decision-making for clinicians and patients. They are advancing multiple NIH-supported clinical research programs that build on the Syn-One Test®’s ability to detect disease-defining pathology, including large, multicenter studies that explore risk and progression in conditions like essential tremor. At the same time, the company is expanding its Arizona-based team and infrastructure to support work at scale.
What Milestone Is CND Life Sciences Particularly Proud Of?
One milestone the company is especially proud of is surpassing 50,000 completed Syn-One Tests for patients across the country. That milestone represents tens of thousands of individuals who were able to move forward with greater confidence in their diagnosis.
In parallel, the company received another NIH Small Business Innovation Research (SBIR) grant in late 2025, its fourth in five years.
Responses provided by Todd Levine, MD, Chief Medical Officer and Co-Founder, CND Life Sciences.
The grant reinforced the importance of the company’s research and its commitment to generating scientific evidence that matters to both clinicians and patients.
How Has Arizona’s Bioscience Ecosystem Supported CND Life Sciences’ Growth?
Arizona’s bioscience ecosystem has played a significant role in CND’s growth. Being named a 2023 AZBio Fast Lane Honoree reflected not only their scientific progress but also the strength of the regional support around them. They have been able to secure more than $12 million in equity funding, multiple NIH grants, and a $4.2 million state award to build and operate their laboratory in Scottsdale. Equally as important, Arizona has enabled them to attract exceptional local talent and collaborate with forward-thinking healthcare organizations like HonorHealth, an early investor and partner. That combination of capital, collaboration, and community has allowed them to scale with purpose while keeping their roots firmly in Arizona.
This spotlight is published in recognition of the World Parkinson Congress (WPC), taking place in Phoenix this May, a fitting moment to highlight the work of a company deeply committed to advancing care for patients with Parkinson’s and related neurodegenerative diseases.
About the Author
Ava Woods is the Marketing & Communications Intern at AZBio, supporting digital communications, content creation, and member engagement initiatives. In her role, Ava assists with social media management, marketing campaigns, event promotion, and storytelling efforts that highlight Arizona’s growing bioscience community. Connect with Ava
About AZBio Member Spotlights
AZBio Member Spotlights are just one of the ways AZBio is building awareness of the health innovations being developed and delivered across the state of Arizona. Telling Arizona’s Bioscience Story is a key goal of Arizona’s Bioscience Roadmap, the nation’s longest-running statewide strategic plan designed to build a robust bioscience sector. Share and enjoy!